Reduced sarco/endoplasmic reticulum Ca(2+) uptake activity can account for the reduced response to NO, but not sodium

T Adachi1, R Matsui, R M Weisbrod

  • 1Vascular Biology Unit, Whitaker Cardiovascular Institute, Boston University Medical Center, Boston, MA, USA.

Circulation
|August 29, 2001
PubMed

Insights

Hypercholesterolemia impairs nitric oxide (NO) relaxation by reducing sarco/endoplasmic reticulum calcium ATPase (SERCA) function. This study reveals SERCA

Area of Science:

  • Vascular Biology
  • Cardiovascular Physiology
  • Smooth Muscle Pharmacology

Background:

  • Hypercholesterolemia (HC) impairs endothelium-dependent relaxation, but the direct effect on smooth muscle response to nitric oxide (NO) is unclear.
  • NO-mediated relaxation involves both cGMP-dependent and -independent pathways, including calcium (Ca2+) handling by sarco/endoplasmic reticulum calcium ATPase (SERCA).

Purpose of the Study:

  • To investigate the roles of cGMP and SERCA in the impaired smooth muscle response to NO and sodium nitroprusside (SNP) in hypercholesterolemic (HC) rabbit aorta.

Main Methods:

  • Used a guanylyl cyclase inhibitor and a SERCA inhibitor (cyclopiazonic acid, CPA) to assess relaxation mechanisms.
  • Measured SERCA activity via 45Ca2+ uptake and SERCA2 protein expression in normal and HC rabbit aorta.

Main Results:

  • SNP-induced relaxation was abolished by the guanylyl cyclase inhibitor, while NO-induced relaxation was only partially inhibited, with residual relaxation blocked by CPA.
  • CPA abolished residual NO-induced relaxation in both normal and HC aorta, but did not affect SNP-induced relaxation.
  • SERCA activity was significantly decreased in HC aorta, despite unchanged SERCA2 protein levels.

Conclusions:

  • NO-induced relaxation, unlike SNP-induced relaxation, is partially mediated by cGMP-independent Ca2+ uptake into the sarco/endoplasmic reticulum.
  • Reduced SERCA pump function in hypercholesterolemia contributes to the impaired vascular smooth muscle response to NO.
Abstract

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...